PMHS.US PMHS
- Market cap
- USD 3.55M
- P/E
- -
- P/B
- 0.67x
- ROE
- -63.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is PMHS.US undervalued?
Graham numberThe Graham number of PMHS cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
PMHS fundamental analysis
No fundamental analysis for PMHS yet.
PMHS stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About PMHS
Polomar Health Services, Inc. operates as a retail compounding pharmacy in the United States. The company owns SlimRx, a weight loss focused online platform connects patients with licensed physicians to prescribe weight loss medications, such as semaglutide compounded with vitamin B-12 and/or metformin; Tofacitinib, it treats rheumatoid arthritis by inhibiting JAK to reduce inflammation and pain; Semaglutide GLP-1, which regulates blood sugar, appetite, and weight in diabete…
Full company profilePMHS financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
PMHS annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2007 | 2008 | 2009 | 2018 | 2019 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | - | - | - | - | - | 34.5K | 41.8K | 58.8K | 648K | 4.89M |
| Gross Profit | - | - | - | - | - | - | 34.5K | 37.6K | 30.9K | 460K | 2.67M |
| Operating Income | -10.5K | -33.6K | -19.8K | -91.1K | -1.79K | -35.7K | -181K | -270K | -1.30M | -10.6M | -342K |
| EBITDA | -10.5K | -33.6K | -19.8K | -91.1K | 271K | -133K | -181K | -411K | -1.04M | -777K | -317K |
| Net Income | -10.5K | -33.6K | -19.8K | -93.3K | 99.1K | -168K | -181K | -417K | -1.34M | -10.7M | -499K |
| EPS | -0.12 | -0.37 | -0.22 | -0.30 | 0.32 | -0.54 | 0.00 | 0.00 | -0.05 | -0.39 | -0.02 |
| Balance Sheet | |||||||||||
| Total Assets | 16.5K | 2.91K | 8.07K | 46.8K | - | - | 261K | 244.00 | 9.95M | 390K | 887K |
| Total Liabilities | - | - | - | 95.4K | - | 35.6K | 74.7K | 13.8K | 14.9K | 1.61M | 97.6K |
| Shareholders' Equity | 16.5K | 2.91K | 8.07K | -48.6K | 627K | -35.6K | 187K | -13.5K | 9.94M | -1.22M | 789K |
| Cash & Short-term Investments | 16.5K | 2.91K | 8.07K | 1.79K | - | - | 226K | 244.00 | 6.19K | 132K | 255K |
| Total Debt | - | - | - | 89.1K | - | 32.7K | 69.7K | 81.7K | 49.2K | 14.9K | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -10.5K | -33.6K | -19.8K | -93.3K | -1.79K | -32.7K | -40.9K | -372K | -1.02M | -396K | 259K |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.00 | 4.00 | 90.9K | 5.00 | 0.00 |
| Free Cash Flow | -10.5K | -33.6K | -19.8K | -93.3K | -1.79K | -32.7K | -40.9K | -372K | -1.11M | -396K | 259K |
| Ratios | |||||||||||
| ROE | -63.7% | -1,156.7% | -245.7% | - | 15.8% | - | -97.0% | - | -13.5% | - | -63.2% |
| ROA | -63.7% | -1,156.7% | -245.7% | -199.3% | - | - | -69.3% | -170,696.7% | -13.5% | -2,743.6% | -56.2% |
| Net Profit Margin | - | - | - | - | - | - | -524.6% | -995.4% | -2,280.2% | -1,650.8% | -10.2% |
| Debt to Equity | - | - | - | - | - | - | 0.37x | - | 0.00x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
PMHS dividends
PMHS has not paid dividends in the last 9 fiscal years.
Last stock split: 1:10 on Nov 1, 2024.
Who owns PMHS
- Insiders 45.18%
- Institutions 0.00%
- Public & others 54.82%
- Shares outstanding 28.4M
- Free float 14.6M
PMHS company profile
- Company name
- PMHS
- Ticker
- PMHS.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Pharmaceutical Retailers
- Employees
- 6
- Fiscal year end
- December
- Address
- 10940 Wilshire Boulevard, Los Angeles, CA, United States, 90024
- Phone
- 212 245 3413
- Website
- polomarsp.com
About PMHS
Polomar Health Services, Inc. operates as a retail compounding pharmacy in the United States. The company owns SlimRx, a weight loss focused online platform connects patients with licensed physicians to prescribe weight loss medications, such as semaglutide compounded with vitamin B-12 and/or metformin; Tofacitinib, it treats rheumatoid arthritis by inhibiting JAK to reduce inflammation and pain; Semaglutide GLP-1, which regulates blood sugar, appetite, and weight in diabetes management; and compounded erectile dysfunction medications inhalable sildenafil. It also includes dermatological formulations for the treatment of acne, alopecia areata, basal cell carcinoma, Becker's nevus, vitiligo, and other skin conditions. In addition, it provides prescription fulfillment services for third party web based tele-health platforms. The company is based in Los Angeles, California.
PMHS management
5- Mr. Terrence M. Tierney J.D.President & Interim CEO · born 1962
- Mr. Charlie Lin C.M.A., CPATreasurer · born 1971
- Mr. George Ronald Hornig J.D.Executive Chairman of the Board · born 1954
- Mr. Douglas J. Beck CPACFO, Treasurer, Principal Financial Officer & Principal Accounting Officer · born 1961
- Mr. Timothy M. PappSecretary & General Counsel